Trial of Verapamil in Chronic Rhinosinusitis

Stopped early · Not applicable · Has a placebo group

Conditions studied: Sinusitis, Nasal Polyps

In brief

Verapamil is an L-type calcium channel blocker(CCB) which has been shown to reduce inflammation in a variety of tissues. Verapamil has also been shown to improve eosinophilic inflammation in an animal model of asthma and also functions as a P-glycoprotein(P-gp) inhibitor. A major subtype of chronic rhinosinusitis(CRS) is characterized by eosinophilic inflammation as well as P-gp overexpression. The goal of this study is to therefore see whether Verapamil may be used to treat CRS.

Key facts

Study ID

NCT02454608

Run by

Benjamin Bleier

People needed

29

Starts

2015-05-01

Expected to finish

2017-05-01

Last updated by the study team

2018-06-14

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients presenting to the Massachusetts Eye and Ear Sinus Center
• Age 18-80 yrs old
• Diagnosed with Chronic Rhinosinusitis with Nasal Polyps according to the EPOS 2012 consensus criteria

You may not qualify if…

• Patients with the following comorbidities:
• GI Hypomotility
• Heart Failure
• Liver Failure
• Kidney Disease
• Muscular Dystrophy
• Pregnant or Nursing Females
• Steroid Dependency
• Patients taking the following medications:
• Aspirin
• Beta-blockers
• Cimetidine(Tagamet)
• Clarithromycin(Biaxin)
• Cyclosporin
• Digoxin
• Disopyramide(Norpace)
• Diuretics
• Erythromycin
• Flecainide
• HIV Protease Inhibitors(Indinavir, Nelfinavir, Ritonavir)
• Quinidine
• Lithium
• Pioglitazone
• Rifampin
• St Johns Wort

Where it is running

• Massachusetts Eye and Ear Infirmary — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.